Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial (Q43942328)

28 November 2017

Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial (English)

1 reference

28 November 2017

gram-positive bacteria

0 references

1 reference

Nathwani D

1

1 reference

28 November 2017

1 December 2001

1 reference

Journal of Hospital Infection

28 November 2017

1 reference

28 November 2017

49 Suppl A

1 reference

28 November 2017

S33-41

1 reference

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Problems with antimicrobial resistance in gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Methicillin-resistant Staphylococcus aureus (MRSA) in the community: who's watching?

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Why do patients with infection remain in hospital once changed to oral antibiotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Antibiotic optimization. An evaluation of patient safety and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Linezolid: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Sequential antibiotic therapy: the right patient, the right time and the right outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Sequential antibiotic therapy: Effective cost management and patient care

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Risk factors for hospital-acquired Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The economic impact of Staphylococcus aureus infection in New York City hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Sequential antimicrobial therapy--the role of quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Pharmacoeconomics of intravenous drug administration

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

The impact of changing pathogens of serious infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

Cost-effectiveness and value of an IV switch

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990032-5

7 January 2021

10.1016/S0195-6701(01)90032-5

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

11926439